Biotech | November 20, 2021
Oravax and Genomma JV to commercialise Covid-19 vaccine in Mexico and Latam
Premas Biotech is the developer of the technology for the Covid-19 vaccine and a shareholder in Oravax Medical
Premas Biotech is the developer of the technology for the Covid-19 vaccine and a shareholder in Oravax Medical
First-of-its-kind Incubator will support companies poised to deliver breakthrough applications in genomics and multiomics
Forty-two per cent Indian patients with Coronary Artery Disease (CAD) or Peripheral Artery Disease (PAD) described “confusion about what I was supposed to do next” as an important barrier to early and accurate diagnosis
Vakrangee’s distribution network across rural India will help penetrate underserved markets
The ground-breaking project, led by Genomics England and NHS England, was established in 2013 to sequence 100,000 whole genomes from NHS patients and their families
The company expects to begin shipping this product before the end of its fiscal first quarter, ending December 31, 2021
A final decision regarding the approval of Ronapreve is expected from the European Commission shortly
The workshop had been organized by the department of surgery at Jawaharlal Nehru Medical College (JNMC), Aligarh Muslim University (AMU), along with the Association of Surgeons of Aligarh (ASA)
In the overall study population through Day 28, no deaths were reported in patients who received Paxlovid as compared to 10 deaths in patients who received placebo
All modules required for regulatory review of Novavax vaccine, including CMC data, are now complete for WHO
Subscribe To Our Newsletter & Stay Updated
